GlassScriptPhysician profile
Richard P Wolff
NPI 1972562718
$2,662.93
in general payments reported to CMS, 2019-2025
27 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $120 · 2021: $22.76 · 2022: $39.45 · 2023: $267 · 2024: $585 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $380.38 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $262.90 | 2019-2025 | Rexulti |
| Corium, LLC | $211.32 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $162.70 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $160.89 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $153.36 | 2019-2025 | Fanapt, Hetlioz |
| Shire North American Group INC | $129.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.57 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $111.83 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $90.72 | 2019 | |
| Abbvie INC. | $87.06 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.41 | 2024-2025 | Caplyta |
| Allergan, INC. | $83.31 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $82.20 | 2019 | |
| Neurocrine Biosciences, INC. | $75.21 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $73.85 | 2019-2025 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $60.41 | 2019 | |
| Ironshore Pharmaceuticals INC. | $59.26 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $52.77 | 2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $50.69 | 2025 | Jornay Pm |
| Alkermes, INC. | $45.33 | 2024-2025 | Lybalvi, Aristada |
| Jazz Pharmaceuticals INC. | $37.17 | 2019-2020 | |
| Almatica Pharma LLC | $29.51 | 2023 | Loreev Xr, Sertraline Hcl |
| Biogen, INC. | $23.39 | 2024 | |
| Adlon Therapeutics L.P. | $15.22 | 2019 | |
| Owp Pharmaceuticals, INC. | $14.40 | 2023 | Lamotrigine, Subvenite |
| Alfasigma USA, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.